Wisdom Financial News APP, Tianjin Ringpu Bio-technology (300119.SZ) announced that, in order to continuously improve the company's strategic layout in the pet health sector, deepen the company's value chain management with Ruipai Pet Hospital and its subsidiary Zhongrui supply chain platform, strengthen the deep strategic synergy in the promotion of pet medical channels and brand building, the company signed an 'Equity Transfer Agreement' in Tianjin on November 7, 2024, planning to acquire a total of 15% equity held by Li Shoujun, Liang Wu, Su Yalada, Li Xudong, Bao Haili, Zhou Zhonghua with its own funds or self-raised funds of 0.131 billion yuan.

The core asset of the target of this transaction, Zhongrui Huapu, is a 17.5179% equity stake in Ruipai Pet Hospital Management Co., Ltd. This acquisition of 15% equity stake in Zhongrui Huapu by the company aims to continue deepening the company's value chain management with Ruipai Pet Hospital and its subsidiary Zhongrui supply chain platform, strengthening the deep collaboration with sales channels, accelerating the comprehensive promotion of the company's pet vaccines to both B-end and C-end customers, and continuously enhancing the strategic synergy effect of channel promotion and brand building.